Results 1 to 10 of about 296,320 (226)

Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy.

JAMA Netw Open, 2023
Key Points Question Is alcohol use associated with achieving a sustained virologic response (SVR) when treating hepatitis C virus (HCV) infection with direct-acting antiviral (DAA) therapy?
Cartwright EJ, Pierret C, Minassian C, Esserman DA, Tate JP, Goetz MB, Bhattacharya D, Fiellin DA, Justice AC, Lo Re V, Rentsch CT.   +10 more
europepmc   +2 more sources

Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials. [PDF]

J Viral Hepat, 2021
Sustained virologic response at posttreatment Week 12 (SVR12) is the widely accepted efficacy endpoint for direct‐acting antiviral agents. Those with hepatitis C virus (HCV) are presenting younger with milder liver disease, potentially reducing need for ...
Gane E, de Ledinghen V, Dylla DE, Rizzardini G, Shiffman ML, Barclay ST, Calleja JL, Xue Z, Burroughs M, Gutierrez JA.   +9 more
europepmc   +2 more sources

Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response. [PDF]

Hepatol Commun, 2021
Hepatocellular carcinoma (HCC) can de novo develop in patients with chronic hepatitis C even after the achievement of sustained virologic response (SVR).
Toyoda H, Hiraoka A, Uojima H, Nozaki A, Shimada N, Takaguchi K, Abe H, Atsukawa M, Matsuura K, Ishikawa T, Mikami S, Watanabe T, Itobayashi E, Tsuji K, Arai T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Okubo T, Ehira T, Kumada T, Tanaka J.   +22 more
europepmc   +2 more sources

Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C [PDF]

Clinical and Molecular Hepatology, 2019
Hepatitis C virus (HCV) infection is a major risk factor for liver cirrhosis and hepatocellular carcinoma (HCC), and is a leading cause of liver-related deaths worldwide. Recently available direct-acting antiviral agent is very safe and highly effective (
Seong Kyun Na, Byung-Cheol Song
doaj   +2 more sources

Modern pharmacotherapy of chronic hepatitis C in patients who failed to achieve sustained virologic response [PDF]

Annals of Mechnikov's Institute, 2020
Introduction. According to WHO experts, about 150 million people suffer from chronic viral hepatitis C (CHC), and 350,000 die annually as a result of liver damage by the hepatitis C virus (HCV).
Kireyev, I.V., Zhabotynska, N.V.
doaj   +3 more sources

Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis

Brazilian Journal of Infectious Diseases, 2010
Background and objectives: Evidence suggests that sustained virologic response to interferon treatment decreases incidence of hepatocellular carcinoma in patients with hepatitis C virus cirrhosis.
Nelson Cheinquer, Hugo Cheinquer, Fernando H. Wolff, Silvia Coelho-Borges   +3 more
doaj   +2 more sources

High sustained virologic response rates, regardless of race or socioeconomic class, in patients treated with chronic hepatitis C in community practice using a specialized pharmacy team. [PDF]

Medicine (Baltimore), 2023
Kuwelker S, Tsai E, Kuo L, Kim J, Van Frank T, Mitchell R, Ramirez R, Guerrero R, Hanysak B, Landaverde C, Rodas F, Lawitz E, Basra T, Nguyen H, Christensen K, Vaughn C, Hinojosa K, Olvera N, Caraballo-Gonzalez E, Pham E, Pedicone LD, Poordad F.   +21 more
europepmc   +2 more sources

ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection [PDF]

Gastroenterology, 2014
BACKGROUND & AIMS The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside polymerase inhibitor), and ribavirin has shown efficacy in patients with hepatitis C virus (HCV ...
Pietro Andreoné, Massimo Colombo, Jeffrey Enejosa, İftihar Köksal, Péter Ferenci, A Maieron, Beat Müllhaupt, Yves Horsmans, Ola Weiland, H. W. Reesink, Lino Rodrigues, Yiran Hu, Thomas Podsadecki, Barry Bernstein   +13 more
openalex   +2 more sources

Augmentation of hepatitis C virus‐specific immunity and sustained virologic response [PDF]

Journal of Viral Hepatitis, 2017
Shikha Shrivastava, Eleanor Wilson, Bhawna Poonia, Lydia Tang, Anu Osinusi, Anita Kohli, Shyam Kottilil   +6 more
openalex   +2 more sources

Hepatitis C reinfection in patients with sustained virologic response at a national hospital in Peru, 2024. [PDF]

Rev Peru Med Exp Salud Publica
Zambrano-Huailla R, Rodríguez Lozano O, Castro Villalobos C, Garavito-Rentería J, Cabezas C.   +4 more
europepmc   +3 more sources